�y��vlog

"While a few metabolism-based drugs for cancer have been developed previously, such as aromatase inhibitors impeding estrogen synthesis in breast cancer and HK2 inhibitors targeting glycolysis in various cancers, these work by suppressing over-activate metabolic pathways," he said.

Research led by Queen Mary University of London's Wolfson Institute of Population Health has found that hormone levels, measured through blood tests, are an important indicator of whether post-menopausal women who are most at risk of developing breast cancer will benefit from aromatase inhibitors such as anastrozole.

Aromatase inhibitors stop the production of oestrogen and reduce the amount made in the body.

Led by Professor Jack Cuzick at Queen Mary University of London, an international team of authors from the UK, Australia, Finland, Germany, Italy, and the USA tested whether measuring oestrogen in the blood could identify which women at increased risk of breast cancer will benefit most from the preventive effects of an aromatase inhibitor.

For patients whose cancers are fueled by hormones, treatment involves surgery, then spending five to 10 years taking either a hormone-blocking drug that can cause birth defects or newer drugs called aromatase inhibitors and a monthly shot to shut down the ovaries.